Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 24Breast Neoplasms 22Head and Neck Neoplasms 14Adenocarcinoma of Lung 11Neoplasms 7Esophageal Neoplasms 7Brain Neoplasms 7Prostatic Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Glioblastoma 5Adenocarcinoma Of Esophagus 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Ovarian Neoplasms 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Skin Neoplasms 2Neoplasms, Squamous Cell 2Mesothelioma, Malignant 2Lymphoid Interstitial Pneumonia 2Laryngeal Diseases 2

Interventions

relacorilant 2pembrolizumab 2cabozantinib 2tariquidar 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenal Cortex Neoplasms × Gefitinib × Clear all
NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
16 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡